Form 6-K ARGENX SE For: Dec 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
Guggenheim on argenx SE (ARGX): 'Long-term Growth Thesis Intact'
December 15, 2025 10:25 AM ESTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $1,085.00 price target on argenx SE (NASDAQ: ARGX).
The analyst comments "We caught up with ARGX following today's announcement regarding the discontinuation of efgartigimod's (anti-FcRn) thyroid eye disease (TED) pivotal study due to futility, which we view as reflective of the specific indication biology with minimal read-across to the Graves'... More
